


Technology Advisory Committee D Interests Register

Topic: Voxelotor for treating haemolytic anaemia in people with sickle cell disease [ID1403]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor David Meads	Committee member	Non-financial professional	Professor Meads declared non- financial professional interests, as the University of Leeds has received funding from BMS for research in an unrelated area.	17/11/2022 22/01/2024	It was agreed his declaration would not prevent Professor Meads from participating in discussion on this appraisal.
Dr Athanasios Saratzis	Committee member	Personal	Dr Athanasios Saratzis declared personal interests in relation to research funded by industry in this area (management of anaemia in surgery).	15/11/2022	As a direct interest Dr Saratzis did not participate in discussions on this appraisal.
Dr Emma Drasar	Clinical expert	Financial	Dr Drasar has received speaking and consultancy fees from GBT and Novartis. She is a PI for Celgene Believe Trial, SI for IMARA study and CI for Roche and has provided support & spoke for UK Thalassaemia Society and Sickle Cell Society.	05/05/2022	It was agreed that her declaration would not prevent Dr Drasar from providing expert advice to the committee.



Professor Paul Telfer	Clinical expert	Financial	Professor Telfer has received research funding from GBT and Bluebird Bio for investigator-led studies on natural history of sickle cell disease in East London Sickle Newborn Cohort Study. He has also received honoraria for advisory board meetings organised by Novartis, Bluebird Bio, Vertex, Global Blood Therapeutics Direct and was the PI in commercial clinical studies sponsored by Novartis, Global Blood Therapeutics and Vertex.	05/05/2022	It was agreed that his declaration would not prevent Professor Telfer from providing expert advice to the committee.
Will Sullivan	Committee Member	Financial	Will is an employee of a consultancy company that provides paid services to various pharmaceutical companies. Will has not provided consultancy work through his employment on the indication or technologies under consideration in this appraisal in the last 12 months.	08/02/2024	It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal.